<?xml version="1.0" encoding="UTF-8"?>
<p>Across OECD countries, funding from governments and compulsory insurance schemes played the largest role in purchasing pharmaceuticals. In 2015, Poles paid the most out-of-pocket for drugs among the OECD countries. According to the OECD, 66% of the costs of the drugs are covered by Polish patients. The situation is similar in Lithuania, and the situation is worse only in Cyprus and Bulgaria. In 2017, funding from governments and compulsory insurance schemes covered 58% of spending on retail pharmaceuticals in Europe. Most of the remainder is financed from out-of-pocket household payments; only 3% of spending is covered by voluntary insurance. In Germany and France, government and compulsory schemes include 80% or more of pharmaceutical costs. By contrast, in Latvia, Poland, and Lithuania, almost two-thirds of pharmaceutical spending was through out-of-pocket payments [
 <xref rid="B13-ijerph-17-08751" ref-type="bibr">13</xref>,
 <xref rid="B19-ijerph-17-08751" ref-type="bibr">19</xref>].
</p>
